2011 annual report - UCB

More documents

Recommendations

Info

Outlook Adriana, living with rheumatoid arthritis Clinical milestones Cimzia ® rheumatoid arthritis (Japan) – filing (January 2012) Cimzia ® ankylosing spondylitis - Phase 3 results (Q1 2012) Cimzia ® juvenile rheumatoid arthritis – start of Phase 3 (Q1 2012) Olokizumab rheumatoid arthritis – Phase 2b results (Q3 2012) CDp7851 fracture healing – Phase 2 results (2012) Vimpat ® epilepsy - monotherapy (U.S.) – Phase 3 results (Q2 2013) Brivaracetam epilepsy - adjunctive therapy - Phase 3 results (H1 2013) Eparatuzumab systemic lupus erythematosus - Phase 3 results (H1 2014) Vimpat ® epilepsy - monotherapy (EU) – Phase 3 results (Q4 2014) ± € 3.1 billion of revenue Cimzia ® ≥ € 1.5 billion peak sales 12 uCB AnnuAl report 2011 € 630 - 660 million of ReBiTDA Vimpat ® ≥ € 1.2 billion peak sales Governance Gerhard Mayr to become Chairman of the Board (May 2012) 2012 GuiDAnCe € 1.60 - 1.70 core epS Neupro ® ≥ € 400 million peak sales TARGeT: 2015-2020
1. Management report of the Board of Directors 1.1. Business performance review 2 1.2. operating and financial review 4 1.3. corporate governance statement 11 1 UCB corporate governance statement 2011
Page 1 and 2: UCB aspires to be the patient-centr
Page 3 and 4: Letter to stakeholders Dear shareho
Page 5 and 6: Helping thousands of patients acros
Page 7 and 8: evenue € million 4 000 3 000 2 00
Page 9 and 10: Central Nervous System Small-molecu
Page 11: Key Figures € million 2007 2008 2
Page 15 and 16: 1.1.2. 2011 key events There have b
Page 17 and 18: neupro ® (rotigotine), available t
Page 19 and 20: 1.2.3. Royalty income and fees 7 UC
Page 21 and 22: 1.2.7. Net profit and adjusted net
Page 23 and 24: 1.3. Corporate Governance Statement
Page 25 and 26: 1.3.2.Shareholders and shareholders
Page 27 and 28: Evelyn du Monceau, Arnoud de Pret,
Page 29 and 30: as to the best way for UCB to becom
Page 31 and 32: Compensation elements and pay for p
Page 33 and 34: Termination arrangements Given the
Page 35 and 36: Long-Term Incentives Vesting in 201
Page 37 and 38: 1.3.7. External audit The General M
Page 39 and 40: The Directors are appointed by the
Page 41 and 42: 30 September 2009, which change of
Page 43 and 44: and the terms of the offer, as well
Page 45 and 46: 2.1. Consolidated income statement
Page 47 and 48: 2.3. Consolidated statement of fina
Page 49 and 50: 2.5. Consolidated statement of chan
Page 51 and 52: Notes to the consolidated financial
Page 53 and 54: vehicles. The Group is still evalua
Page 55 and 56: Royalty income Royalties are recogn
Page 57 and 58: 3.2.15. Leases Leases are classifie
Page 59 and 60: instrument with the same terms as t
Page 61 and 62: Profit-sharing and bonus plans The
Page 63 and 64:
3.4. Financial risk management The
Page 65 and 66:
3.4.3. Liquidity risk Liquidity ris
Page 67 and 68:
€ million level 1 level 2 level 3
Page 69 and 70:
3.6.2. Other non-current assets hel
Page 71 and 72:
3.11. Other operating income/expens
Page 73 and 74:
Income taxes recognised in the inco
Page 75 and 76:
3.19. Goodwill € million 2011 201
Page 77 and 78:
3.22. Financial and other assets 3.
Page 79 and 80:
€ million 2011 2010 Balance at 1
Page 81 and 82:
3.27.3. Performance share plan The
Page 83 and 84:
3.27.9. Share appreciation rights (
Page 85 and 86:
3.28.2. Finance lease liabilities -
Page 87 and 88:
3.31.2. Unused tax losses The amoun
Page 89 and 90:
The fair value of plan assets amoun
Page 91 and 92:
3.34. Trade and other liabilities 3
Page 93 and 94:
3.36. Financial instruments by cate
Page 95 and 96:
The following table shows the split
Page 97 and 98:
On 24 April 2008, the Group has iss
Page 99 and 100:
€ million 2011 2010 Short-term em
Page 101 and 102:
name and office Holding parent Cana
Page 103 and 104:
name and office Holding parent Sout
Page 105 and 106:
We hereby confirm that, to the best
Page 107 and 108:
Statutory Auditor’s Report to the
Page 109 and 110:
6.1. Introduction In accordance wit
Page 111 and 112:
6.5. Summary of significant account
Page 113 and 114:
Global Reporting Initiative Disclos
Page 115 and 116:
Human Resources and Environmental D
Page 117 and 118:
Scope and Reporting Principles Scop
Page 119 and 120:
107 UCB csr performance report 2011
show all

2011 annual report - UCB

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?